DexCom Added to Raymond James Analyst Current Favorite List
DexCom Analyst Ratings
Raymond James Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $115
Redburn Atlantic Adjusts Price Target on DexCom to $80 From $130
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
Dexcom's Stock Downgrade: A Temporary Setback or a Buying Opportunity?
DexCom Options Spot-On: On July 29th, 68,305 Contracts Were Traded, With 164.54K Open Interest
Stocks Making the Biggest Moves Midday: Walt Disney, DexCom, McDonald's, On Semiconductor and More
DexCom Is Maintained at Equal-Weight by Barclays
Tandem Diabetes Care, DexCom Say Health Canada Authorizes T:Slim X2 Insulin Pump
Behind the Scenes of DexCom's Latest Options Trends
Stocks on Sale: DexCom, Biogen, and L3Harris
Express News | Tandem Diabetes Care and Dexcom Announce the T:Slim X2 Insulin Pump With Dexcom G7 Cgm Compatibility Is Authorized for Sale by Health Canada
Express News | Dexcom Outlook FY Revenue USD 4,000-4,350 Million
Dexcom's Strong Market Position and Growth Potential Affirm Buy Rating Despite Initial Rebate Confusion
Express News | Dexcom : Barclays Cuts Target Price to $113 From $138
Is Beaten-Down Dexcom Stock a Buy on the Dip?
Barclays Maintains DexCom(DXCM.US) With Hold Rating, Maintains Target Price $113
Analysts' Opinions Are Mixed on These Healthcare Stocks: MacroGenics (MGNX) and Dexcom (DXCM)
With A 44% Price Drop For DexCom, Inc. (NASDAQ:DXCM) You'll Still Get What You Pay For